Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.38 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.37 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.37 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.32 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.32 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.32 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.32 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.32 |
| ▸ | CHRNA7 known ✓ | P36544 | 2/20 | 0.32 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.32 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BBOX1 | O75936 | 6/20 | 0.33 |
| ▸ | GALR3 | O60755 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974755 | 0.98 | ACHE (0.39) | ACHEADRA2AADRA1ABLMMAPT | |
| Sulfuric Acid SCHEMBL16196071 | 0.90 | ACHE (0.34) | ACHEADRA2AADRA1ABLMMAPT | |
| Hydrochloric Acid SCHEMBL8448319 | 0.87 | ACHE (0.50) | ACHEADRA2AADRA1ABBOX1SMN1; SMN2 | |
| SCHEMBL170245 | 0.84 | ACHE (0.52) | ACHEADRA2AADRA1ABBOX1SMN1; SMN2 | |
| SCHEMBL6445293 | 0.83 | ADRA2A (0.33) | ACHEADRA2AADRA1ABLMMAPT | |
| SCHEMBL15397899 | 0.83 | ACHE (0.45) | ACHEBBOX1SMN1; SMN2LMNATSHR | |
| SCHEMBL612764 | 0.81 | APOBEC3A (0.44) | ACHESMN1; SMN2LMNATSHRRAB9A | |
| Hydrochloric Acid SCHEMBL7765956 | 0.79 | ACHE (0.39) | ACHEADRA2AADRA1ABLMMAPT | |
| SCHEMBL4972961 | 0.78 | BBOX1 (0.53) | BBOX1 | |
| SCHEMBL2834524 | 0.78 | BBOX1 (0.53) | BBOX1CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014999-B1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GENZYME CORP (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6692732-B2 | Administering cationic polymers to mammals to prevent poisons or antigens from microorganisms such as bacteria, viruses, fungi or parasites; deactivation | GENZYME CORPORATION | 2004-02-17 | — | — | US | disclosed |
| US-20040009145-A1 | IONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| US-6482402-B1 | BACTERICIDE AND CATIONIC POLYMER | GELTEX PHARMACEUTICALS, INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | GELTEX PHARMACEUTICALS, INC. | 2002-08-22 | — | — | US | disclosed |
| US-6290947-B1 | IN ONE EMBODIMENT, THE POLYMER IS A COPOLYMER COMPRISING A MONOMER HAVING A PENDANT AMMONIUM GROUP AND A HYDROPHOBIC MONOMER. | GELTEX PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| EP-1014999-A1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 2000-07-05 | — | — | EP | disclosed |
| US-6007803-A | ADMINISTERING TO MAMMAL A CATIONIC POLYMER TO INHIBIT PATHOGENIC TOXINS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-5925379-A | REMOVING BILE SALTS FROM PATIENT BY ADMINISTERING INTERPENETRATING POLYMER NETWORK COMPRISING CATIONIC POLYMER | GELTEX PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1999015186-A1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | PIGS, ANTXR2, MSN | ACHE 1151/4885ADRA2A 2964/4885ADRA1A 2912/4885 |
| US-20040009145-A1 | IONIC POLYMERS AS TOXIN-BINDING AGENTS | PIGS, ANTXR2, MSN | ACHE 1151/4885ADRA2A 2964/4885ADRA1A 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.